What is atypical pneumonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Atypical pneumonia is a type of lung infection caused by organisms different from those that cause typical pneumonia, primarily Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydia pneumoniae, as stated in the guidelines for the management of adults with community-acquired pneumonia 1. The term "atypical pneumonia" refers to the specific pathogens listed above, which can cause pneumonia in patients with no pathogen identified by routine diagnostic testing.

  • Symptoms of atypical pneumonia include a persistent dry cough, low-grade fever, headache, fatigue, and mild chest pain.
  • For treatment, macrolide antibiotics like azithromycin are first-line therapy, as recommended in the guidelines for the management of community-acquired pneumonia in adults 1.
  • Alternatively, doxycycline or fluoroquinolones like levofloxacin may be used.
  • Most cases can be treated at home with rest, adequate hydration, and over-the-counter medications for fever and pain.
  • Atypical pneumonia differs from typical pneumonia in its presentation, with less severe symptoms, gradual onset, and minimal physical exam findings despite significant X-ray abnormalities.
  • These organisms lack cell walls, making them resistant to beta-lactam antibiotics like penicillins and cephalosporins, which is why specific antibiotic choices are crucial for effective treatment, as noted in the guidelines 1. The recommended empirical regimen should routinely cover the 3 most common pathogens that cause severe CAP, all of the atypical pathogens, and most of the relevant Enterobacteriaceae species, as stated in the guidelines for the management of community-acquired pneumonia in adults 1.

From the FDA Drug Label

Atypical pneumonia due to Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila

  • Atypical pneumonia is caused by certain bacteria, including:
    • Chlamydophila pneumoniae
    • Mycoplasma pneumoniae
    • Legionella pneumophila Clinical success rates for atypical pneumonia were 96% for Chlamydophila pneumoniae, 96% for Mycoplasma pneumoniae, and 70% for Legionella pneumophila 2

From the Research

Definition of Atypical Pneumonia

Atypical pneumonia is a clinical syndrome characterized by a less severe clinical course than typical bacterial pneumonia, caused by a variety of different organisms including:

  • Mycoplasma pneumoniae
  • Chlamydiae (such as Chlamydia pneumoniae)
  • Rickettsiae
  • Viruses
  • Legionella pneumophila 3 It is also characterized by systemic complaints rather than respiratory symptoms, with causative pathogens including Mycoplasma, Chlamydia, Legionella, and respiratory viruses (influenza, adenovirus, respiratory syncytial virus) 4.

Causative Organisms

The most common causative organisms of atypical pneumonia are:

  • Mycoplasma pneumoniae
  • Chlamydia pneumoniae
  • Legionella species 5 These organisms are not detectable with Gram stain and cannot be cultured using standard methods.

Treatment

The therapeutic approach for atypical pneumonias is different from that for typical pneumonia, with antibiotics such as macrolides (e.g. erythromycin, azithromycin) or tetracyclines (e.g. doxycycline) being used to treat atypical pneumonia 3, 4. For community-acquired pneumonia, the Japanese pneumonia guidelines propose a differential diagnosis for typical bacterial pneumonia and atypical pneumonia to select an appropriate antibiotic, with a β-lactam drug plus a macrolide or tetracycline, or only fluoroquinolone being considered for elderly individuals and patients with underlying diseases 5. Short-course regimens, such as a 5-day course of levofloxacin, may also be effective in treating atypical community-acquired pneumonia caused by atypical pathogens 6.

Clinical Efficacy

Studies have shown that azithromycin and levofloxacin are effective in treating atypical pneumonia, with high clinical success rates and rapid symptom resolution 7, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The problems of treating atypical pneumonia.

The Journal of antimicrobial chemotherapy, 1993

Research

Atypical pneumonias: therapeutic possibilities.

International journal of antimicrobial agents, 1993

Research

Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1991

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.